Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)

v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)
Convertible Series A Preferred Stock
Preferred Stock
Convertible Series B-1A Preferred Stock
Preferred Stock
Convertible Series B-1 Preferred Stock
Preferred Stock
Convertible Series B-2 Preferred Stock
Preferred Stock
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Retroactive application of reverse recapitalization $ (1,000) $ (317) $ (1,050)     $ 30,563 $ (20,651)   $ 7,545
Retroactive application of reverse recapitalization (in shares) (1,000,000) (316,848) (1,050,695)     30,563,009      
Balance (as previously reported) at Dec. 31, 2019 $ 1,000 $ 317 $ 1,050 $ 0   $ 10,686 33,538,813 $ (38,402,816) (4,850,950)
Balance (as previously reported) (in shares) at Dec. 31, 2019 1,000,000 316,848 1,050,695 0   10,686,191      
Beginning balance at Dec. 31, 2019           $ 41,249 33,518,162 (38,402,816) (4,843,405)
Beginning balance (in shares) at Dec. 31, 2019           41,249,200      
Common stock issued           $ 51 176,974   177,025
Common stock issued (in shares)           50,844      
Series B-2 convertible preferred stock issued           $ 13 50,000   50,013
Series B-2 convertible preferred stock issued (in shares)           13,168      
Stock-based compensation             88,803   88,803
Net income (loss)               (1,590,056) (1,590,056)
Ending balance at Mar. 31, 2020           $ 41,313 33,833,939 (39,992,872) (6,117,620)
Ending balance (in shares) at Mar. 31, 2020           41,313,212      
Balance (as previously reported) at Dec. 31, 2019 $ 1,000 $ 317 $ 1,050 $ 0   $ 10,686 33,538,813 (38,402,816) (4,850,950)
Balance (as previously reported) (in shares) at Dec. 31, 2019 1,000,000 316,848 1,050,695 0   10,686,191      
Beginning balance at Dec. 31, 2019           $ 41,249 33,518,162 (38,402,816) $ (4,843,405)
Beginning balance (in shares) at Dec. 31, 2019           41,249,200      
Common stock issued to settle note conversion (in shares)                 1,138,199
Net income (loss)                 $ (6,649,481)
Ending balance at Sep. 30, 2020           $ 42,744 42,180,599 (45,052,297) (2,828,954)
Ending balance (in shares) at Sep. 30, 2020           42,743,945      
Beginning balance at Mar. 31, 2020           $ 41,313 33,833,939 (39,992,872) (6,117,620)
Beginning balance (in shares) at Mar. 31, 2020           41,313,212      
Stock-based compensation             93,466   93,466
Net income (loss)               102,287 102,287
Ending balance at Jun. 30, 2020           $ 41,313 33,927,405 (39,890,585) (5,921,867)
Ending balance (in shares) at Jun. 30, 2020           41,313,212      
Common stock issued           $ 293 1,411,774   1,412,067
Common stock issued (in shares)           292,534      
Common stock issued to settle note conversion           $ 1,138 3,960,988   3,962,126
Common stock issued to settle note conversion (in shares)           1,138,199      
Warrants issued as compensation for services             2,689,684   2,689,684
Stock-based compensation             190,749   190,749
Net income (loss)               (5,161,712) (5,161,712)
Ending balance at Sep. 30, 2020           $ 42,744 42,180,599 (45,052,297) (2,828,954)
Ending balance (in shares) at Sep. 30, 2020           42,743,945      
Retroactive application of reverse recapitalization $ (1,000) $ (317) $ (1,050) $ (4)   $ 31,746 (21,786)   7,589
Retroactive application of reverse recapitalization (in shares) (1,000,000) (316,848) (1,050,695)   (4,167) 31,745,786      
Balance (as previously reported) at Dec. 31, 2020 $ 1,000 $ 317 $ 1,050 4   $ 11,228 46,387,649 (90,179,720) (43,778,472)
Balance (as previously reported) (in shares) at Dec. 31, 2020 1,000,000 316,848 1,050,695   4,167 11,227,676      
Beginning balance at Dec. 31, 2020           $ 42,974 46,365,863 (90,179,720) (43,770,883)
Beginning balance (in shares) at Dec. 31, 2020           42,973,462      
Common stock issued           $ 333 6,926,753   6,927,086
Common stock issued (in shares)           333,121      
Proceeds from issuance of common stock for exercise of warrant           $ 1,496 7,498,522   7,500,018
Proceeds from issuance of common stock for exercise of warrant (in shares)           1,496,216      
Reclassification of settlement liability upon issuance of warrant             60,851,779   60,851,779
Stock-based compensation             371,698   371,698
Net income (loss)               (25,488,874) (25,488,874)
Ending balance at Mar. 31, 2021           $ 44,803 122,014,615 (115,668,594) 6,390,824
Ending balance (in shares) at Mar. 31, 2021           44,802,799      
Balance (as previously reported) at Dec. 31, 2020 $ 1,000 $ 317 $ 1,050 $ 4   $ 11,228 46,387,649 (90,179,720) (43,778,472)
Balance (as previously reported) (in shares) at Dec. 31, 2020 1,000,000 316,848 1,050,695   4,167 11,227,676      
Beginning balance at Dec. 31, 2020           $ 42,974 46,365,863 (90,179,720) (43,770,883)
Beginning balance (in shares) at Dec. 31, 2020           42,973,462      
Issuance of common stock for exercise of warrants and Unit Purchase Options                 $ 16,699,489
Common stock issued for consulting services (in shares)                 834,045
Net income (loss)                 $ (62,269,946)
Ending balance at Sep. 30, 2021           $ 54,810 161,362,260 (152,449,666) 8,967,404
Ending balance (in shares) at Sep. 30, 2021           54,810,338      
Beginning balance at Mar. 31, 2021           $ 44,803 122,014,615 (115,668,594) 6,390,824
Beginning balance (in shares) at Mar. 31, 2021           44,802,799      
Common stock issued           $ 71 1,562,201   1,562,272
Common stock issued (in shares)           71,056      
Effect of Merger and recapitalization, net of redemptions and issuance costs           $ 2,530 (26,618,326)   (26,615,796)
Effect of Merger and recapitalization, net of redemptions and issuance costs (in shares)           2,529,730      
Common stock issued pursuant to PIPE financing, net of issuance costs           $ 1,000 8,099,000   8,100,000
Common stock issued pursuant to PIPE financing, net of issuance costs (in shares)           1,000,000      
Common stock issued for advisor services           $ 200 4,849,800   4,850,000
Common stock issued for advisor services (in shares)           200,000      
Modification of option awards pursuant to Merger             1,014,640   1,014,640
Modification of warrants pursuant to Merger             2,330,572   2,330,572
Stock-based compensation             938,118   938,118
Net income (loss)               (16,007,973) (16,007,973)
Ending balance at Jun. 30, 2021           $ 48,604 114,190,620 (131,676,567) (17,437,343)
Ending balance (in shares) at Jun. 30, 2021           48,603,585      
Common stock issued           $ 511 1,134,305   $ 1,134,816
Common stock issued (in shares)           511,065     511,065
Common stock and warrants issued in private placement, net of issuance costs           $ (2,727) (27,355,496)   $ (27,358,223)
Common stock and warrants issued in private placement, net of issuance costs (in shares)           2,727,273      
Issuance of common stock for exercise of warrants and Unit Purchase Options           $ 2,334 9,197,137   9,199,471
Issuance of common stock for exercise of warrants and Unit Purchase Options (in shares)           2,334,370      
Common stock issued for consulting services           $ 634 7,924,877   $ 7,925,511
Common stock issued for consulting services (in shares)           634,045     634,045
Stock-based compensation             1,559,825   $ 1,559,825
Net income (loss)               (20,773,099) (20,773,099)
Ending balance at Sep. 30, 2021           $ 54,810 $ 161,362,260 $ (152,449,666) $ 8,967,404
Ending balance (in shares) at Sep. 30, 2021           54,810,338